Top 20 life sciences deals list shows 2025 M&A rebound

CURRENT FULL VERSION: PharmaShots has published its “Top 20 Life Sciences Deals of 2025,” a year-end roundup created with DealForma data that captures just how active the sector became by the end of the year. The ranking highlights a mix of acquisitions, business-unit purchases, divestitures, and R&D partnerships, with examples ranging from Shionogi’s $2.5 billion Mitsubishi Tanabe Pharma business-unit purchase to large strategic transactions involving Pfizer, Merck, Sanofi, Thermo Fisher Scientific, Siemens, and Eli Lilly. Lilly’s planned acquisition of Centessa Pharmaceuticals, for example, was valued at about $7.8 billion, including roughly $6.3 billion upfront plus contingent value rights tied to future FDA approvals in narcolepsy, idiopathic hypersomnia, and other indications. (pharmashots.com)

The backdrop is a much stronger M&A market than the industry saw in 2024. DealForma reported that global healthcare and life sciences M&A climbed to 585 transactions in 2025, with announced value of $269.3 billion including contingents, versus $140.8 billion in 2024. Deloitte likewise described 2025 as a year that started slowly, then rebounded in the second half as buyers returned to external innovation and more targeted portfolio building. (dealforma.com)

Several of the year’s biggest transactions help explain the ranking’s tone. DealForma identified Pfizer’s acquisition of Metsera, Merck’s acquisitions of Verona Pharma and Cidara Therapeutics, Sanofi’s acquisition of Blueprint Medicines, and Thermo Fisher Scientific’s acquisition of Clario as standout examples of 2025’s scale. In earlier 2025 data, DealForma also pointed to Sanofi’s $9.5 billion Blueprint deal, Siemens’ $5.1 billion Dotmatics acquisition, and Torrent’s roughly $3 billion purchase of JB Pharma as leading second-quarter transactions. Across partnerships, large bets also landed on AI and China-linked innovation, including BioNTech’s alliance with Bristol Myers Squibb and Pfizer’s deal with 3SBio. Private capital was active too: PharmaShots separately reported that Blackstone closed its BXLS VI fund at $6.3 billion, the largest life sciences vehicle of its kind, after committing about $2 billion over the prior 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. (dealforma.com)

Industry observers described a more selective market than the headline numbers alone might suggest. Deloitte said buyers favored derisked assets and competitive therapeutic areas, with a shift toward acquiring single assets or smaller portfolios that could be folded into existing pipelines. Nature similarly reported that 2025 biopharma dealmaking was driven by a string of high-value M&A transactions, while Fierce Biotech cited Leerink analysts saying deal count and value both recovered after a period of “conservatism and recovery.” PharmaShots’ separate roundup of the top 20 healthcare IPOs of 2025 pointed in the same direction on the public-markets side: the year’s biggest raises were concentrated in scaled, technology-enabled, and often revenue-generating businesses, led by Medline Industries at $7.2 billion, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million. The IPO list also highlighted investor interest in AI-driven drug discovery, precision medicine, digital care platforms, oncology, and metabolic disease. (deloitte.com)

That selectivity is especially relevant for veterinary professionals and industry watchers. Even though the PharmaShots ranking is centered on human life sciences, the same capital markets logic often shapes what happens downstream in veterinary diagnostics, therapeutics, software, and service consolidation. Research tools and data platforms such as Dotmatics, AI-enabled discovery partnerships, and demand for commercial-stage or late-stage assets all point to a market rewarding technologies that can shorten development timelines or strengthen existing portfolios. The IPO data reinforces that point by showing continued investor preference for AI-enabled solutions, advanced diagnostics, and precision-focused platforms. That can influence the availability, valuation, and strategic direction of companies serving companion animal and livestock health, even if those effects arrive later. This is an inference based on broader market patterns and adjacent deal activity, including commentary that veterinary pharma and clinic assets remain areas of private equity and strategic interest. (dealforma.com)

There’s also a practical takeaway for clinics and veterinary business leaders: broader life sciences consolidation can affect supplier relationships, diagnostics ecosystems, lab software, and pricing power over time. DealForma noted that services and software accounted for a large share of transaction volume in 2025, while biopharma and diagnostics drove much of the value creation. If that pattern continues, veterinary teams may see more cross-market borrowing of digital tools, lab infrastructure, and commercialization strategies first developed for human healthcare. And if private equity remains willing to pursue large take-private transactions such as CVC Capital Partners’ proposed roughly €10.9 billion acquisition of Recordati, that would be another sign that sponsors still see value in scaled specialty-pharma platforms, including businesses with rare-disease exposure. (dealforma.com)

Why it matters: The main lesson from the top-deals list isn’t just that 2025 was busy. It’s that buyers were willing to spend again, but mostly where assets looked differentiated, nearer to market, or strategically essential. For veterinary professionals, that’s a useful lens for reading future moves in animal health: investors and acquirers may be more interested in proven platforms, diagnostics, specialty therapeutics, and software than in earlier, riskier bets. The year’s IPO and fund-raising patterns support the same conclusion. (deloitte.com)

What to watch: In 2026, watch for continued appetite for bolt-on acquisitions, AI-enabled discovery platforms, and commercial or late-stage assets, plus any clearer spillover into veterinary pharma, diagnostics, and pet care consolidation. Also watch whether strong specialist fund-raising and public-market receptivity for AI, precision medicine, and diagnostics continue to reinforce deal activity. Analysts from ING and IQVIA both expect deal momentum to continue after 2025’s rebound. (think.ing.com)